Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Medtronic
Boehringer Ingelheim
Moodys
Harvard Business School

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Arbor Pharms Llc Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Arbor Pharms Llc
International Patents:309
US Patents:22
Tradenames:24
Ingredients:15
NDAs:23

Drugs and US Patents for Arbor Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc ERYTHROMYCIN erythromycin TABLET;ORAL 061621-001 Approved Prior to Jan 1, 1982 AB RX No No   Start Trial   Start Trial
Arbor Pharms Llc ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate TABLET;ORAL 061904-001 Approved Prior to Jan 1, 1982 BX RX No Yes   Start Trial   Start Trial
Arbor Pharms Llc TRIPTODUR KIT triptorelin pamoate FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 208956-001 Jun 29, 2017 RX Yes Yes   Start Trial   Start Trial
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes 8,026,279   Start Trial Y Y   Start Trial
Arbor Pharms Llc ERYTHROCIN STEARATE erythromycin stearate TABLET;ORAL 060359-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Arbor Pharms Llc TRIPTODUR KIT triptorelin pamoate FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 208956-001 Jun 29, 2017 RX Yes Yes 10,166,181   Start Trial Y   Start Trial
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No 9,066,936   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Arbor Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 5,583,141   Start Trial
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 5,583,141   Start Trial
Arbor Pharms Llc GLIADEL carmustine IMPLANT;INTRACRANIAL 020637-001 Sep 23, 1996 4,757,128   Start Trial
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 5,958,961   Start Trial
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 5,736,555   Start Trial
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 5,958,961   Start Trial
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 5,583,141   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ARBOR PHARMS LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Lotion 0.5% ➤ Subscribe 2017-09-01

Supplementary Protection Certificates for Arbor Pharms Llc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1718641 CA 2012 00013 Denmark   Start Trial
1718641 PA2012004 Lithuania   Start Trial PRODUCT NAME: AZILSARTANUM MEDOXOMILUM; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/734/011, 2011 12 07, EU/1/11/735/001 - EU/1/11/735/011 20111207
1620113 300756 Netherlands   Start Trial PRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN DE BEHANDELING VAN ROSACEA; FIRST REGISTRATION NO/DATE: MA117/01101 20150402; NATIONAL REGISTRATION NO/DATE: RVG 115310 20150504
1620113 PA2015033 Lithuania   Start Trial PRODUCT NAME: IVERMECTINUM; NAT. REGISTRATION NO/DATE: LT/1/15/3726/001 - LT/1/15/3726/005 20150513; FIRST REGISTRATION: MA117/01101 20150402
1620113 C 2015 036 Romania   Start Trial PRODUCT NAME: IVERMECTINA; NATIONAL AUTHORISATION NUMBER: RO7674/2015/01, RO7674/2015/02, RO7674/2015/03, RO7674/2015/04, RO7674/2015/05; DATE OF NATIONAL AUTHORISATION: 20150526; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): MALTA MA117/01101; DATE OF FIRST AUTHORISATION IN EEA: 20150402
1718641 C20120005 00053 Estonia   Start Trial PRODUCT NAME: IPREZIV - ASILSARTAANMEDOKSOMIIL;REG NO/DATE: C(2011) 9281 FINAL 07.12.2011
1620113 92915 Luxembourg   Start Trial PRODUCT NAME: IVERMECTINE POUR SON USAGE DANS LE TRAITEMENT DE LA ROSACEA; FIRST REGISTRATION: 20150402
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.